Bio-Technology General
Executive Summary
Human superoxide dismutase Phase II trials for prevention of reperfusion damage in heart attack patients are in progress. The product is being developed under an agreement with Bristol-Myers. Other firms developing SOD products include Chiron, in conjunction with Pharmacia and DDI Pharmaceuticals.